Edgewise Therapeutics (EWTX) recently reported second quarter 2026 results that showed a wider net loss of $57.33 million and a basic loss per share of $0.53, compared with the prior year period.

Despite the wider loss, Edgewise Therapeutics shares have shown strong momentum, with a 30 day share price return of 11.09% and an 85.98% year to date share price return. The 1 year total shareholder return of 212.16% and 3 year total shareholder return above 5x reflect how investors have reacted over a longer period.

If you are weighing what this kind of move might mean for other opportunities in healthcare, it could be a useful moment to scan 42 healthcare AI stocks.

Edgewise Therapeutics shares have rerated sharply, while the latest analyst target still sits above the current price. The spread between that reference point and today’s valuation raises a simple question: Is the stock already fair, or not yet there?

Preferred Price-to-Book Multiple of 10.7x: Is It Justified For Edgewise Therapeutics?

With Edgewise Therapeutics last closing at $44.17 and trading on a P/B ratio of 10.7x, investors are effectively paying a high premium to the company’s current book value. That stands in contrast to the broader US Pharmaceuticals sector, where the average P/B sits at 2.5x.

The P/B multiple compares a company’s market value to its net assets on the balance sheet. For a business like Edgewise Therapeutics that is still in the development stage and currently unprofitable, a higher P/B often reflects expectations around the future value of its pipeline rather than its present financials.

In this case, the market is assigning a substantially richer valuation than the sector average. The 10.7x P/B suggests investors are pricing in strong potential from assets such as sevasemten and the broader precision medicine pipeline, even though Edgewise Therapeutics reports no meaningful revenue and continues to record losses. Compared with the US Pharmaceuticals industry average of 2.5x, the stock trades on more than four times the sector level, which signals that expectations embedded in the price are materially higher than those for many peers.

On a peer comparison, however, Edgewise Therapeutics screens differently. Its 10.7x P/B is below the peer group average of 47.2x. Within that smaller set of companies with similar characteristics, it does not sit at the extreme end of valuations.

Result: Price-to-book ratio of 10.7x (OVERVALUED)

However, Edgewise Therapeutics still carries clear risks, including its current losses of $197.222 million and its reliance on clinical trial progress for pipeline assets.

Next Steps

With sentiment on Edgewise Therapeutics so divided between its potential and its risks, it makes sense to move quickly and review the full picture yourself. Take a closer look at the balance of risk and reward by checking the 1 key reward and 2 important warning signs

Looking for more investment ideas beyond Edgewise Therapeutics?

Do not stop with Edgewise Therapeutics. Use this momentum to scan other stocks so you are not missing opportunities that better fit your goals and risk comfort.

• Target resilient companies by checking the 80 resilient stocks with low risk scores that may help you keep your portfolio steadier when markets move.
• Hunt for potential bargains by reviewing the 52 high quality undervalued stocks that combine quality fundamentals with pricing that might still be attractive.
• Strengthen your income plan by using the 10 dividend fortresses that could help you focus on higher yielding stocks with more robust payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.